Disc Medicine Insider Yu Jonathan Yen-Wen Buys Shares
COO Yu Jonathan Yen-Wen acquired 18,612 shares of Disc Medicine on June 16, 2026.
Key Points
- On June 16, 2026, Disc Medicine's COO Yu Jonathan Yen-Wen bought 18,612 shares at $9.86 each, totaling $183,514.
- Shares of NasdaqGM:IRON traded at $70.21 with a market cap of $2.68 billion, and a forward P/E indicating it's not profitable.
- Peers like RA Capital Management increased their stake by 474,089 shares, while Morgan Stanley maintained a buy rating with an $85 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, Yu Jonathan Yen-Wen, the Chief Operating Officer of Disc Medicine, Inc. (NasdaqGM:IRON), purchased 18,612 shares of the company. This insider transaction was executed at an average price of $9.86 per share, amounting to a total value of $183,514.
Insider Buying and Selling at Disc Medicine, Inc.
Yu Jonathan Yen-Wen's recent acquisition of 18,612 shares on June 16, 2026, was not part of a pre-planned trading program. The purchase at $9.86 per share demonstrates his confidence in the company's future prospects. Additionally, other insiders like Chief Financial Officer Jean Franchi sold shares in planned transactions earlier in April 2026.
Other Institutional Activity in Disc Medicine
Several institutional investors have been adjusting their positions in Disc Medicine. RA Capital Management, L.P. significantly increased its holdings by 474,089 shares, bringing its total to 2,450,221 shares valued at approximately $156.7 million. Wellington Management Group LLP also boosted its stake by 217,102 shares, ending with 1,735,376 shares worth about $111 million. On the other hand, BlackRock, Inc. slightly reduced its position by 1,149 shares, holding 2,273,831 shares valued at $145.4 million.
Disc Medicine, Inc. Stock Down 12.3%
Shares of Disc Medicine (NasdaqGM:IRON) traded near $70.21. The company has a market cap of approximately $2.68 billion and a forward P/E ratio indicating it is not currently profitable. The stock has experienced a 52-week low of $40.00 and a high of $99.50. Its 50-day moving average is $68.45, while the 200-day moving average stands at $73.11. The company exhibits a robust current ratio of 24.00 and a quick ratio of 23.45, with a debt-to-equity ratio of 4.51.
$IRON stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Morgan Stanley maintained its buy rating for Disc Medicine on June 16, 2026, with a price target of $85. This aligns with the strong buy consensus among analysts, who have set a mean price target of $101.55 based on 11 opinions. Other firms like Wells Fargo and Truist Securities also continue to recommend the stock with buy ratings.
About Disc Medicine
Disc Medicine, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. It focuses on discovering, developing, and commercializing treatments for serious blood-related diseases. With a portfolio targeting conditions like anemia and erythropoietic porphyrias, the company is committed to modifying biological pathways related to red blood cell formation and function. Founded in 2017, Disc Medicine is led by CEO Dr. John D. Quisel and employs over 150 people.
Bottom Line
Yu Jonathan Yen-Wen's insider purchase highlights his confidence in Disc Medicine's potential. Investors often watch insider transactions for insights, though these actions are not definitive indicators of future stock performance. As always, these insights are based on past filings and publicly available information.
Get Disc Medicine, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IRON, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.